Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT07353931·Phase 3·INTERVENTIONAL

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

EloralintideWeight lossInflammationRecruiting

Status

Recruiting

Phase

Phase 3

Enrollment

900

Locations

161

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.

Interventions

Treatment arms and agents.

DRUG

Eloralintide

Administered SC

DRUG

Placebo

Placebo administered SC

Timeline

From registration to results.

  1. First posted

    Jan 21, 2026

  2. Study start

    Feb 9, 2026

  3. Primary completion

    Mar 2028

  4. Study completion

    May 2028

  5. Results posted

    Not reported

  6. Registry updated

    Jul 17, 2026

Outcomes

What the study measures.

Primary outcomes

Percent Change from Baseline in Body Weight

Time frame · Baseline, Week 64

Percent Change from Baseline in Body Weight

Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score

Time frame · Baseline, Week 64

Change from Baseline in the WOMAC Pain Subscale Score

Secondary outcomes

Change from Baseline in Systolic Blood Pressure (SBP)

Time frame · Baseline, Week 64

Change from Baseline in SBP

Percent Change from Baseline in Triglycerides

Time frame · Baseline, Week 64

Percent Change in Baseline in Triglycerides

Change from Baseline in Short Form-36 (SF-36 v2) Acute Form Physical Functioning Domain Score

Time frame · Baseline, Week 64

Change from Baseline in SF-36 v2 Score

Percent Change from Baseline in High Sensitivity, C-reactive Protein (hsCRP)

Time frame · Baseline, Week 64

Percent Change from Baseline in hsCRP

Change from Baseline in the WOMAC Physical Function Subscale Score

Time frame · Baseline, Week 40, Week 64

Change from Baseline in the WOMAC Physical Function Subscale Score

Change from Baseline WOMAC Pain Subscale Score

Time frame · Baseline, Week 40

Change from Baseline WOMAC Pain Subscale Score

Change from Baseline in Distance Walked During the 6-Minute Walk Test

Time frame · Baseline, Week 64

Change from Baseline in Distance Walked During the 6-Minute Walk Test

Change from Baseline in Body Mass Index (BMI)

Time frame · Baseline, Week 64

Change from Baseline in BMI

Change in Medication Use

Time frame · Baseline, Week 64

Change in Medication Use

Change from Baseline in SF-36v2 Acute Form Domain Scores With Exception of the Physical Functioning Domain Score

Time frame · Baseline, Week 64

Change from Baseline in SF-36v2 Acute Form Domain Scores With Exception of the Physical Functioning Domain Score

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening * Have a stable body weight (less than 5% body weight change) for 90 days prior to screening * Have tried at least once to lose weight through diet but were unsuccessful * Have osteoarthritis of the knee and at least one of the following conditions: * Be over 50 years old * Have morning knee stiffness that lasts about 30 minutes * Have a crackling or grinding sound or feeling in the knee Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes, type 2 diabetes, or any other type of diabetes * Have an active knee infection * Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure * Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure * Have taken medications or alternative remedies intended for weight loss within 90 days of screening

Study locations

161 registered sites.

Argentina · Belgium · Brazil · Canada · China · Czechia · Denmark · Germany · Japan · Mexico · Puerto Rico · South Korea · Taiwan · United Kingdom · United States. Showing up to 24 locations stored in the fast local snapshot.

AMR Clinical

Mobile, Alabama, United States

Care Access - 801 South Power Road, Mesa

Mesa, Arizona, United States

Elite Pain and Spine Institute - South Crimson Road

Mesa, Arizona, United States

Elite Clinical Studies, LLC

Phoenix, Arizona, United States

Tucson Orthopaedic Institute - North Wyatt Drive

Tucson, Arizona, United States

Ark Clinical Research - Fountain Valley

Fountain Valley, California, United States

Wolverine Clinical Trials

Santa Ana, California, United States

Encompass Clinical Research

Spring Valley, California, United States

Diablo Clinical Research, Inc.

Walnut Creek, California, United States

Skylight Health Research - Colorado Springs

Colorado Springs, Colorado, United States

Westside Center for Clinical Research

Jacksonville, Florida, United States

Care Access - St. Petersburg

St. Petersburg, Florida, United States

Conquest Research

Winter Park, Florida, United States

Orita Clinical Research

Decatur, Georgia, United States

Medical Research Partners

Ammon, Idaho, United States

Great Lakes Clinical Trials - Ravenswood

Chicago, Illinois, United States

Qualmedica Research, LLC

Evansville, Indiana, United States

AMR Clinical

Newton, Kansas, United States

Monroe Biomedical Research - Louisville

Louisville, Kentucky, United States

Skylight Health Research - Burlington

Burlington, Massachusetts, United States

Care Access - Quincy

Quincy, Massachusetts, United States

Ellipsis Research Group - Brooklyn - 7th Street

Brooklyn, New York, United States

Rochester Clinical Research - Buffalo

Buffalo, New York, United States

NYC Research INC

Long Island City, New York, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Eloralintide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsEloralintide trial dashboard →